Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 2Q Earnings Report

Roth Capital reiterated a Buy rating on Cytori Therapeutics, Inc. (NASDAQ: CYTX), and cut the price target to $4.00 (from $6.00), following the company's 2Q15 earnings release. EPS of $0.03 beat the consensus estimates of -$0.03. CYTX ended the quarter with $23.8 million in cash.

Analyst Joseph Pantginis commented, "Cytori announced 2Q15 results, posting EPS of $0.03 compared with our estimate of $0.06 and ended the quarter with $23.8 million in cash. With initiation of the Phase III STAR and data expected from the Phase IIb ACTOA study, we believe Cytori is making important strides to increase visibility and advance its multiple clinical programs. Maintain Buy and lowering target to $4 from $6."

For an analyst ratings summary and ratings history on Cytori Therapeutics, Inc. click here. For more ratings news on Cytori Therapeutics, Inc. click here.

Shares of Cytori Therapeutics, Inc. closed at $0.42 yesterday.

You May Also Be Interested In

• Ford (F) earnings top estimates in Q1 amid strength in Pro unit; stock up
• Reckitt Benckiser (RKT:LN) (RBGLY) PT Lowered to GBP51 at Berenberg
• Deutsche Boerse AG (DB1:GR) (DBOEY) PT Lowered to EUR193 at JPMorgan